MiCo BioMed Co Ltd
KOSDAQ:214610
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.5), the stock would be worth ₩7 765.22 (239% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | ₩2 290 |
0%
|
| 3-Year Average | 2.5 | ₩7 765.22 |
+239%
|
| 5-Year Average | 3.3 | ₩10 269.58 |
+348%
|
| Industry Average | 2.9 | ₩8 990.83 |
+293%
|
| Country Average | 1.1 | ₩3 455.5 |
+51%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
M
|
MiCo BioMed Co Ltd
KOSDAQ:214610
|
19.2B KRW | 0.7 | -1.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.6 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.8 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 2.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2.3 |
| Max | 2 461.2 |
Other Multiples
MiCo BioMed Co Ltd
Glance View
MiCo BioMed Co. Ltd. engages in the development, manufacture and sale of in vitro diagnosis medical devices and diagnostic reagents. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2015-06-22. The firm operates its business through three segments. The Molecular Diagnosis segment mainly manufactures and sells products such as nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment mainly manufactures and supplies products such as complex diagnostics, anemia meters, blood glucose meters, medical devices and strips. The Immunodiagnostic Business segment mainly produces and sells immunodiagnostic devices and immunodiagnostic kits.
